Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure
HAYA Therapeutics’ drugs hit targets in the dark genome, the part of the genome that does not code for proteins but plays a key role in regulating gene expression. With the Series A funding, the startup will enter Phase 1 with of a genetic medicine addressing fibrosis that leads to a type of heart failure. The post Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure appeared first on MedCity News.
HAYA Therapeutics’ drugs hit targets in the dark genome, the part of the genome that does not code for proteins but plays a key role in regulating gene expression. With the Series A funding, the startup will enter Phase 1 with of a genetic medicine addressing fibrosis that leads to a type of heart failure.
The post Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure appeared first on MedCity News.
